CDSCO panel recommends Biological E 14-valent paediatric vaccine against S pneumonia

Published On 2022-09-02 07:25 GMT   |   Update On 2024-02-15 12:36 GMT

New Delhi: Biological E Limited on Thursday announced that the Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) reviewed and approved the Phase 3 infants' clinical trial data and recommended for manufacture its 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) against S pneumonia infection, in single-dose...

Login or Register to read the full article

New Delhi: Biological E Limited on Thursday announced that the Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) reviewed and approved the Phase 3 infants' clinical trial data and recommended for manufacture its 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) against S pneumonia infection, in single-dose and multi-dose presentations.

A press release from the city-based vaccine maker said the PCV14 can be administered to infants at six, 10 and 14 weeks of age. Streptococcus pneumoniae infection continues to be a leading cause of child mortality under 5 years of age in India and in developing countries.

Read also: Biological E to infuse over Rs 1800 crore to ramp up production of vaccines, injectables, RnD

With the PCV14 vaccine, BE hopes to contribute to the prevention of invasive pneumococcal disease and protect millions of lives globally.

The safety analysis of the vaccine revealed that all the adverse events were mild to moderate in their intensity and with no grade-3 & 4 events reported.

Read also: Biological E Corbevax booster shot approved for 18 years and above vaccinated with Covaxin, Covishield

Mahima Datla, Managing Director, Biological E Limited said, "We are delighted with this remarkable development. BE's PCV14 will protect millions of infants worldwide and contribute to the prevention of invasive pneumococcal disease."
With this recommendation from SEC and the anticipated formal approval from Drugs Controller General of India (DCGI) thereafter, India will have yet another important lifesaving vaccine for paediatric use. Biological E would be also working with WHO and other global regulatory agencies to make this vaccine available globally, she added.

Read also: Eyestem raises Rs 51 crore in Series A round led by Biological E, Alkem, Natco and others

Founded and led by Dr. DVK Raju, Biological E. Limited commenced its operations in 1953. The company currently has four strategic business units Branded Formulations, Speciality Generic Injectables, Synthetic Biology and Vaccines and Biologics.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News